| Literature DB >> 29552120 |
Min Fang1, Jingping Yuan2, Mengyuan Chen3, Zongwen Sun4, Lulu Liu3, Guoping Cheng5, Hangjie Ying1, Shifeng Yang5, Ming Chen1.
Abstract
The present study was performed to quantify tumor neo-vessels, macrophages and fibroblasts in the tumor microenvironment of hepatocellular carcinoma (HCC) and explore the prognostic factors of HCC. The distribution of tumor neo-vessels, macrophages and fibroblasts was quantified by immunohistochemistry and inverted microscopy with the CRi Nuance multispectral imaging system, and the correlation of these parameters with the clinico-pathological characteristics and overall survival of the patients was analyzed. The number of tumor neo-vessels and macrophages, and density of the fibroblasts, as calculated by the thickness of the tumor stroma in the tumor microenvironment, ranged from 51-429 (median, 218), 110-555 (median, 259) and 35.6-555.5 µm (median, 247.0), respectively. Using the median values as a cutoff, the cases were stratified into high- and low-density groups. Survival analysis demonstrated that the high-density groups regarding macrophages (χ2=5.249, P=0.022) and fibroblasts (χ2=18.073, P<0.001) had a significantly shorter disease-free survival (DFS) than the low-density groups. The high-density tumor neo-vessel group had a shorter DFS with a median of 5 months than the low-density group with a median of 7 months; however, there was no statistical significance between these two groups (χ2=1.663, P=0.197). Regarding the above three stromal components combined, all of the cases were classified into low-, middle- and high-density groups. Survival analysis demonstrated that the high-density group of stromal components had a shorter DFS than the other two groups with a median of 3 months (χ2=14.439, P=0.001). Multivariate analysis by Cox regression indicated that cirrhosis, metastasis stage, as well as macrophage and fibroblast density were independent prognostic factors. In conclusion, the key elements in the tumor microenvironment, including tumor neo-vessels, macrophages and fibroblasts, were heterogenic in HCC tissues and have significant roles in HCC invasion and metastasis. Stromal components are associated with the prognosis of patients with HCC; the higher the density of stromal components, the poorer the prognosis of patients with HCC.Entities:
Keywords: hepatocellular neoplasms; metastasis; pathology; tumor microenvironment
Year: 2018 PMID: 29552120 PMCID: PMC5840703 DOI: 10.3892/ol.2018.7946
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Major demographic and clinicopathological characteristics of hepatocellular carcinoma cases (n=101).
| Item | Value |
|---|---|
| Age (years) | 51 (19–75) |
| Sex | |
| Male | 90 (89.1) |
| Female | 11 (10.9) |
| Tumor size (cm) | |
| ≤5 | 26 (25.7) |
| >5 | 75 (74.3) |
| Tumor number | |
| Single | 86 (85.1) |
| Multiple | 15 (14.9) |
| AFP (ng/ml) | |
| ≤200 | 54 (53.5) |
| >200 | 47 (46.5) |
| Liver cirrhosis | |
| No | 58 (57.4) |
| Yes | 43 (42.6) |
| Venous infiltration | |
| No | 53 (52.5) |
| Yes | 48 (47.5) |
| TNM stage | |
| Early (Stage I, II) | 47 (46.5) |
| Advanced (Stage III, IV) | 54 (53.5) |
| Tumor recurrence | |
| No | 37 (36.6) |
| Yes | 64 (63.4) |
| Distant metastasis | |
| No | 46 (45.5) |
| Yes | 55 (54.5) |
| DFS (Median, range) | 5.0 (0–54.0) |
Values are expressed as median (range) or n (%). TNM, tumor-nodes-metastasis; AFP, α-fetoprotein; DFS, disease-free survival.
Figure 1.Immunohistological analysis of hepatocellular carcinoma tissue sections. Representative immunohistochemical images of (A and B) tumor neo-vessels stained for CD105 and of (C and D) macrophages stained for CD68. B and D display the corresponding images following signal unmixing with the CRi Nuance multispectral imaging system (scale bar, 50 µm).
Figure 2.Heterogeneous density of stromal components in the hepatocellular carcinoma microenvironment. (A and B) Tumor neo-vessels in HCC with (A) scattered and discrete distribution and (B) high density. (C and D) Macrophages in HCC tissue with (C) low and (D) high density. (E and F) Fibroblasts in HCC tissues with (E) low and (F) high density as determined by immunohistochemical detection of α-smooth muscle actin (scale bar, 50 µm).
Association between the density of tumor neo-vessels, macrophages and α-SMA expression, and clinicopathological features.
| Tumor neo-vessel density | Macrophage density | α-SMA expression | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feature | Low (n=49) | High (n=49) | χ2 | P-value | Low (n=51) | High (n=40) | χ2 | P-value | Low (n=48) | High (n=52) | χ2 | P-value |
| Age (years) | 0.511 | 0.634 | 1.000 | 0.102 | 4.408 | 0.060 | ||||||
| <60 | 39 (52.0) | 36 (48.0) | 38 (55.1) | 31 (44.9) | 32 (42.1) | 44 (57.9) | ||||||
| ≥60 | 10 (43.5) | 13 (56.5) | 13 (59.1) | 9 (40.9) | 16 (66.7) | 8 (33.3) | ||||||
| Gender | 0.102 | 0.749 | 0.071 | 0.789 | 0.670 | 0.529 | ||||||
| Male | 44 (50.6) | 43 (49.4) | 45 (55.6) | 36 (44.4) | 44 (49.4) | 45 (50.6) | ||||||
| Female | 5 (45.5) | 6 (54.5) | 6 (60.0) | 40 (40.0) | 4 (36.4) | 7 (63.6) | ||||||
| Tumor size (cm) | 2.631 | 0.164 | 0.679 | 0.467 | 1.322 | 0.265 | ||||||
| ≤5 | 9 (36.0) | 16 (64.0) | 14 (63.6) | 8 (36.4) | 15 (57.7) | 11 (42.3) | ||||||
| >5 | 40 (54.8) | 33 (45.2) | 37 (53.6) | 32 (46.4) | 33 (44.6) | 41 (55.4) | ||||||
| Tumor number | 1.968 | 0.261 | 0.633 | 0.539 | 0.545 | 0.568 | ||||||
| Single | 39 (47.0) | 44 (53.0) | 43 (54.4) | 36 (45.6) | 40 (46.5) | 46 (53.5) | ||||||
| Multiple | 10 (66.7) | 5 (33.3) | 8 (66.7) | 4 (33.3) | 8 (57.1) | 6 (42.9) | ||||||
| AFP (ng/ml) | 1.027 | 0.418 | 0.038 | 0.845 | 3.344 | 0.075 | ||||||
| ≤200 | 24 (45.3) | 29 (54.7) | 27 (55.1) | 22 (44.9) | 30 (56.6) | 23 (43.4) | ||||||
| >200 | 25 (55.6) | 20 (44.4) | 24 (57.1) | 18 (42.9) | 18 (38.3) | 29 (61.7) | ||||||
| Liver cirrhosis | 0.377 | 0.682 | 0.091 | 0.832 | 2.425 | 0.156 | ||||||
| No | 27 (47.4) | 30 (52.6) | 29 (54.7) | 24 (45.3) | 24 (41.4) | 34 (58.6) | ||||||
| Yes | 22 (53.7) | 19 (46.3) | 22 (57.9) | 16 (42.1) | 24 (57.1) | 18 (42.9) | ||||||
| Venous infiltration | 0.368 | 0.686 | 2.724 | 0.139 | 0.334 | 0.689 | ||||||
| No | 24 (47.1) | 27 (52.9) | 23 (47.9) | 25 (52.1) | 24 (45.3) | 29 (54.7) | ||||||
| Yes | 25 (53.2) | 22 (46.8) | 28 (65.1) | 15 (34.9) | 24 (51.1) | 23 (48.9) | ||||||
| TNM stage | 1.027 | 0.418 | 2.247 | 0.145 | 1.054 | 0.324 | ||||||
| Early | 20 (44.4) | 25 (55.6) | 20 (47.6) | 22 (52.4) | 20 (42.6) | 27 (57.4) | ||||||
| Advanced | 29 (54.7) | 24 (45.3) | 31 (63.3) | 18 (36.7) | 28 (52.8) | 25 (47.2) | ||||||
| Tumor recurrence | 0.180 | 0.832 | 0.437 | 0.661 | 0.109 | 0.837 | ||||||
| No | 18 (52.9) | 16 (47.1) | 20 (60.6) | 13 (39.4) | 17 (45.9) | 20 (54.1) | ||||||
| Yes | 31 (48.4) | 33 (51.6) | 31 (53.4) | 27 (46.6) | 31 (49.2) | 32 (50.8) | ||||||
| Distant metastasis | 0.164 | 0.840 | 2.247 | 0.145 | 0.511 | 0.113 | ||||||
| No | 22 (47.8) | 24 (52.2) | 20 (47.6) | 22 (52.4) | 18 (39.1) | 28 (60.9) | ||||||
| Yes | 27 (51.9) | 25 (48.1) | 31 (63.3) | 18 (36.7) | 30 (55.6) | 24 (44.4) | ||||||
Values are expressed as n (%). TNM, tumor-nodes-metastasis; AFP, alpha-fetoprotein.
Figure 3.Cumulative DFS of patients with HCC. (A) Tumor neo-vessels were not associated with DFS of patients with HCC. (B and C) Patients in the high-density (B) macrophage and (C) α-SMA expression groups had a higher risk of death. (D) Combined features accurately indicated DFS of patients with HCC. HCC, hepatocellular carcinoma; DFS, disease-free survival; CI, confidence interval; SMA, smooth muscle actin. Group I, all three components were expressed at a low level; group II, 1 or 2 components were expressed at a high level; group III, 3 components were expressed at a high level.
Multivariate analyses of factors associated with DFS.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Clinicopathological factor | P-value | HR | 95% CI | P-value | HR | 95% CI |
| Age (<60 vs. ≥60 years) | 0.284 | 1.014 | 0.988–1.040 | |||
| Sex (female vs. male) | 0.381 | 0.588 | 0.180–1.926 | |||
| Tumor size (≤5 vs. >5) | 0.979 | 0.989 | 0.442–2.216 | 0.181 | 1.552 | 0.815–2.956 |
| Tumor number (single vs. multiple) | 0.402 | 0.558 | 0.142–2.188 | |||
| AFP (≤200 vs. >200) | 0.088 | 1.742 | 0.921–3.293 | |||
| Liver cirrhosis (no vs. yes) | 0.020 | 0.514 | 0.294–0.899 | |||
| Venous infiltration (no vs. yes) | 0.141 | 0.277 | 0.050–1.530 | 0.696 | 1.114 | 0.649–1.910 |
| TNM stage (early vs. advanced)[ | 0.098 | 4.955 | 0.745–32.937 | |||
| Tumor recurrence (no vs. yes) | <0.001 | 28.416 | 7.979–101.205 | <0.001 | 17.035 | 5.644–51.415 |
| Distant metastasis (no vs. yes) | 0.411 | 0.755 | 0.386–1.476 | |||
| Tumor neo-vessel density (low vs. high) | 0.794 | 1.000 | 0.997–1.002 | |||
| Macrophage density (low vs. high) | 0.008 | 1.004 | 1.001–1.007 | 0.025 | 1.870 | 1.082–3.233 |
| α-SMA expression (low vs. high) | 0.005 | 1.004 | 1.001–1.007 | |||
Early, TNM stage I/II; advanced, TNM stage III/IV. DFS, disease-free survival; SMA, smooth muscle actin; TNM, tumor-nodes-metastasis; HR, hazard ratio; CI, confidence interval.